The latest news from the national collection came out of the fifth batch of time

With the normalization of national harvesting, varieties, time have become traceable, pharmaceutical enterprises should do a good job in advance of market research, adjust their product structure, make a response.1, the fifth batch of time has traces to follow Recently, CCTV for the national centralized procurement of the normal news, made a special report, confirmed the annual two batches of volume procurement of the normal news.On November 5, 2020, China's first centralized belt procurement of crown bracket, 10 varieties of winning bid, the price from the average price of 13,000 yuan to about 700 yuan, crown bracket suddenly from the "ceiling price" to "floor price", causing an industry uproar.Chen Jinfu, deputy director of the State Administration of Medical Security, said: "High-value medical supplies in the field of falsely high costs, the circulation of the field of 'gold sales' disease has been a long time, resulting in a high burden on the people, clinical use of drugs, including supplies is very chaotic."Dong Zhaoxuan, Deputy Director of the Tendering and Procurement Department of the Price Recruitment Division of the State Administration of Medical Security, said: "In the field of pharmaceuticals, centralized belt procurement will be carried out normally, and it is expected that two batches of belt procurement will be carried out each year; Infact, according to the wind and medicine talk combing, from the second batch, each batch of volume procurement of the approximate time, has become traceable.Second batch schedule: : 2019.11.28Statistics: 2019.12.10 - 12 days to complete the statisticsrelease: 20 20.01.13 - 44 days to publish the current price and offerquotation: 2020.01.17 - 47 days to complete the announcement of the quotation - four days after the release of the preparation time.Spring Festival: 2020.01.25 - 8 days before the Spring Festival completedthird batch schedule:report: 2020.06.22statistics: 2020.07.09 - 17 days to complete statisticsrelease: 2020.07.29 - 37 days release price andCurrent price: 2020.08.20 - 59 days to complete the announcement of the quotation fourth batch schedule: offer: 2020.12.10 statistics: 2021.01.01 - 21 days to complete the statistics released: January 15 - published the volume, 18 days to complete the Quote: February 3, Quote Spring Festival: 2021.02.11 - 8 days before the Spring Festival completed Now, according to the timetable, the twice-yearly national collection has gradually normalized and fixed, perhaps next June, the fifth batch of volume procurement will arrive as scheduled.
2, the medical insurance catalogue, the use of large varieties into the collection On January 15, the Premier held an executive meeting of the State Council, the deployment of the "two sections" period to strengthen the affected by the epidemic disaster and low-security groups of life security; The meeting pointed out that in recent years, the state has promoted major reforms in the procurement and use of centralized drug belt, and by the end of last year had carried out three batches of collecting, covering an average price reduction of 54% of the drugs, saving more than 53 billion yuan a year in costs and benefiting hundreds of millions of patients. In the near future, the fourth batch of collection will be carried out, and expand the range of high-value medical supplies collection. The meeting called for, in accordance with the deployment of medical reform, adhere to the three-doctor linkage, and promote the normalization of drug collection and institutionalization. First, in accordance with the basic and clinical principles, focus on the basic medical insurance drug catalog of large quantities, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of various types of drugs and consumables. Public medical institutions should participate in the collection. The study made special arrangements for the procurement of "orphan drugs" for the treatment of rare diseases. Second, qualified generic drugs, original research drugs and matching preparations are all in the general name to participate in the collection, through quality and price fair competition to produce selected enterprises and drugs, supplies. Medical institutions should ensure that priority is given to the use of selected medicines and that procurement is maximized as needed. Selected enterprises to ensure that price reduction does not reduce the quality, do not reduce the efficacy, to ensure supply. Strengthen the production, circulation and use of selected drugs and consumables throughout the chain supervision. Third, the collection should reduce the burden on patients at the same time, taking into account the reasonable profits of enterprises, promote the pharmaceutical and consumables industry in the competition to improve concentration, promote product innovation and upgrading, the cost of saving medical insurance in accordance with the provisions to give medical institutions residual incentives, and strive to make this reform to achieve patients and enterprises, medical institutions have benefited. 3, injection large-scale collection began 2021, January 15, Shanghai Sunshine Procurement Network issued the "National Drug Centralized Procurement Document", marking the fourth batch of national drug belt procurement officially began, February 3, price declaration and auction determination. Data show that the fourth batch of 45 products, 80 regulations, involving the number of pharmaceutical companies is expected to exceed 120. According to the research institute, 8 of the 45 varieties have injection varieties, 3 eye drops and the rest are oral dosage forms. It is worth noting that the official launch of the fourth batch of national harvesting means that the centralized procurement of large clinical varieties of injections has officially begun. The eight injectable varieties shortlisted for this year are dosso-tea-alkali injections, ibuprofen injections, amin bromine injections, propofol medium-long-chain fat milk, paroxeb injections, pythola-lax injections, boron-zomi injections and injection-based bivaldidine, which accounted for more than 30% of the total sample hospital revenue of 45 varieties in 2019. In 2019, China's public hospital end-use drug injection market size of more than 630 billion yuan, the first 20 clinical varieties of total sales of more than 100 billion yuan, the eight injection varieties into the national harvest, or dozens of pharmaceutical companies have an impact on sales revenue. In terms of health insurance varieties, of the 45 varieties, 7 are National Health Insurance Class A drugs, 35 are Class B drugs, and 2 non-medicated drugs are ibuprofen injections and injections of bivaldidine. Combined with the spirit of the executive meeting of the State Council on January 15th, the focus will be on the basic medical insurance drug catalog of large quantities of drugs, procurement of high amounts of drugs into the procurement scope. To some extent, in order to cage for birds, save the health insurance fund, the large number of varieties used in the health insurance catalogue, will be given priority to be included in the collection, from several rounds of collection of variety data can also clearly see this trend. With the normalization of national harvesting, varieties, time have become traceable, pharmaceutical enterprises should do a good job in advance of market research, adjust their product structure, make a response. (Cypress Blue)